SCHEMBL1855433

SCHEMBL1855433

COCCN(C)C(=O)Cc1c[nH]c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.59
PKM P14618 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 3/20 0.56
LMNA P02545 1/20 0.56
NPC1 O15118 1/20 0.54
CDK4 P11802 6/20 0.52
CCND1 P24385 5/20 0.52
KDM4E B2RXH2 2/20 0.51
HPGD P15428 1/20 0.51
MC4R P32245 1/20 0.49
MC5R P33032 1/20 0.49
MC3R P41968 1/20 0.49
HTR1A P08908 2/20 0.49
HTR2A P28223 2/20 0.49
HTR2C P28335 2/20 0.49
HTR2B P41595 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851966 0.85 NPSR1 (0.62) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL1854926 0.85 NPSR1 (0.62) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL796067 0.81 PKM (0.62) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL29756365 0.81 PKM (0.62) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL1851225 0.81 NPSR1 (0.58) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL29992703 0.81 PKM (0.64) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL1852400 0.81 PKM (0.64) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL25172859 0.79 NPSR1 (0.61) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL24723809 0.79 CDK4 (0.77) NPSR1PKMSMN1; SMN2ALDH1A1MEN1
SCHEMBL25169836 0.78 CDK4 (0.61) NPSR1PKMSMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA NPSR1 4334/4885PKM 310/4885SMN1; SMN2 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.